Table 1.

Drugs included in the four investigated pharmaceutical groups, and number of people in a cohort of people with intellectual disability (ID) and a reference group from the general population (gPop) with at least one prescription during the study period

	gPop	ID
Anxiolytics
N05BA01 diazepama	83	198
N05BA02 chlordiazepoxidea	< 5	< 5
N05BA04 oxazepama	157	264
N05BA06 lorazepama	< 5	19
N05BA09 clobazama	< 5	< 5
N05BA12 alprazolama	42	58
N05BB01 hydroxyzine	128	162
N05 BC01 meprobamate	< 5	< 5
N05BE01 buspirone	15	22
Hypnotics and sedatives
N05CC01 chloral hydratea	< 5	< 5
N05CD02 nitrazepama	26	43
N05CD03 flunitrazepama	16	14
N05CD05 triazolama	< 5	< 5
N05CD08 midazolama	< 5	< 5
N05CF01 zopiclonea	173	214
N05CF02 zolpidema	112	83
N05CF03 zaleplona	8	< 5
N05CM02 clomethiazolea	< 5	57
N05CM05 scopolamine	< 5	< 5
N05CM06 propiomazine	164	186
N05CM09 Valerianae radix	< 5	< 5
Antidepressants
N06AA04 clomipramine	14	42
N06AA06 trimipramine	< 5	< 5
N06AA09 amitriptyline	43	34
N06AA10 nortriptyline	5	< 5
N06AA21 maprotiline	< 5	< 5
N06AB03 fluoxetine	31	29
N06AB04 citalopram	124	206
N06AB05 paroxetine	19	33
N06AB06 sertraline	100	127
N06AB08 fluvoxamine	< 5	< 5
N06AB10 escitalopram	73	88
N06AF03 phenelzine	< 5	< 5
N06AF04 tranylcypromine	< 5	< 5
N06AG02 moclobemide	< 5	< 5
N06AX02 tryptophan	< 5	< 5
N06AX03 mianserin	25	27
N06AX11 mirtazapine	148	141
N06AX12 bupropion	27	16
N06AX16 venlafaxine	78	54
N06AX18 reboxetine	9	< 5
N06AX21 duloxetine	59	33
N06AX22 agomelatine	9	< 5

^aAlso included in the group “GABA-agonists”